| Audience | Patients, caregivers, clinicians, neuro-oncology readers |
| Primary Topic | CBD for anxiety and depressive symptoms in primary brain tumors |
| Source | Read the full article |
CBD for Anxiety in Brain Tumor Patients: What This Early Trial Found
CBD for anxiety in brain tumor patients is often discussed as a plausible symptom-relief strategy, but plausible is not the same as proven. In this small crossover randomized trial, 600 mg/day of oral CBD for three weeks did not outperform placebo for anxiety or depressive symptoms, and the placebo period looked numerically better. The bigger lesson is not that CBD has been definitively disproven here, but that this particular study does not support benefit and leaves major uncertainty because it stopped early.
For patients and families: Anxiety and low mood are not side issues for people living with brain tumors. They shape sleep, concentration, functioning, relationships, and quality of life. A headline that says “CBD did not work” could sound simple, but this paper deserves a slower read. It tells us that this exact regimen, in this exact study, did not help more than placebo. It does not tell us that every cannabinoid strategy is useless for every neuro-oncology patient.
For clinicians: This is one of the better-designed studies in a space that often runs on weak evidence. That makes its negative finding important. At the same time, the small sample, early termination, study burden, and crossover attrition mean the safest clinical reading is modest: there is no supportive signal here for routine use of oral CBD 600 mg/day over three weeks for anxiety or depressive symptoms in stable primary brain tumor patients with elevated baseline anxiety.
For researchers and policy readers: This paper is also a reminder that feasibility matters. A theoretically elegant protocol can fail in practice if recruitment burden is too high or if patients are unwilling to pursue a cannabinoid intervention inside a trial structure. That does not just affect statistics. It affects whether a research question can be answered convincingly at all.
| Study Type | Double-blind, placebo-controlled crossover randomized clinical trial, early terminated |
| Population | Adults with stable primary brain tumors and clinically relevant anxiety at screening, S-STAI at least 44 |
| Exposure or Intervention | Oral CBD 600 mg/day for 3 weeks, tablets with greater than 99% CBD and less than 0.1% THC |
| Comparator | Matched placebo for 3 weeks, with crossover after more than 2-week washout |
| Primary Outcomes | Anxiety symptoms by S-STAI, depressive symptoms by CES-D, and adverse events by CTCAE grading |
| Sample Size or Scope | 20 randomized, 15 completed both treatment periods; target enrollment had been 55 |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI | 10.1093/nop/npag025 |
| Funding or Conflicts | Investigator-initiated study funded by the Anita Veldman Foundation; authors reported no conflict of interest |
The investigators enrolled adults with stable primary brain tumors who also had clinically relevant anxiety symptoms at baseline. Participants were randomized to receive either oral CBD first or placebo first for three weeks, then completed a washout period longer than two weeks before crossing over to the other treatment. The CBD product was highly purified, with greater than 99% CBD and less than 0.1% THC. Anxiety was measured with the State-Trait Anxiety Inventory state subscale, depressive symptoms with the CES-D, and adverse events with standard toxicity grading.
The study did not find evidence that CBD improved anxiety or depressive symptoms more than placebo. In fact, reductions in symptoms were generally larger during the placebo period. The posterior probability that CBD improved anxiety was only 19%, and for depressive symptoms 11%. The posterior median treatment difference favored placebo rather than CBD for both anxiety and depressive symptoms. Clinically significant anxiety remained common after both periods, present in 50% after placebo and 59% after CBD. Adverse events were broadly similar across conditions, although one patient developed a maculo-papular rash during CBD, possibly related to a carrier substance.
How Strong Is the Evidence on CBD for Anxiety in Brain Tumor Patients?
By cannabis research standards, this is a relatively strong design because it is randomized, blinded, placebo controlled, and crossover. That gives it more interpretive value than retrospective reports or uncontrolled observations. But the paper also sits in the category of a small, underpowered negative trial. The early stop, incomplete crossover completion, and limited sample mean it can argue against a clear benefit signal in this protocol more comfortably than it can prove the intervention has no value in all real-world contexts.
The biggest limitation is simple: the study did not reach anything close to its intended enrollment. It randomized 20 patients rather than the planned 55, and only 15 completed both treatment periods. That makes false negatives easier. The treatment window was also short, just three weeks per period, which may or may not be enough time for some symptom patterns. The population was heterogeneous across tumor types and grades, which matters when symptom burden, concurrent treatment history, and neuropsychiatric context can vary widely. Because this was a crossover design in a medically complex population, attrition and burden are not minor background details, they are central to how much weight the results deserve. Finally, the authors themselves moved from “we did not see benefit here” to discouraging further investigation, and that final step is stronger than the data comfortably support.
This study gives meaningful negative evidence, but not a final answer. For now, the most justified conclusion is that high-purity oral CBD at 600 mg/day for three weeks did not improve anxiety or depressive symptoms over placebo in this small randomized crossover trial of adults with primary brain tumors. That is useful to know. It should guide expectations downward, while leaving room for humility about what this study could and could not settle.
? Join the Conversation
Questions about whether this kind of evidence should change real-world care decisions? Ask Dr. Caplan →
Want to discuss symptom relief, uncertainty, and cannabis evidence with others? Join the forum discussion →
Have thoughts on this? Share it:
Frequently Asked Questions
1. Did the study find that CBD helped anxiety in brain tumor patients?
No. This study did not find that oral CBD 600 mg/day improved anxiety more than placebo over three weeks.
2. Did CBD help depressive symptoms?
No clear benefit was seen for depressive symptoms either. The symptom changes were numerically more favorable during the placebo period.
3. Was this a high-quality study?
It used a stronger design than many cannabis papers, randomized, blinded, placebo controlled, and crossover. But it was also small and early terminated, which limits confidence.
4. How many patients were studied?
Twenty patients were randomized, and fifteen completed both treatment periods. The original plan had been to enroll fifty-five.
5. What dose of CBD did they use?
The study used 600 mg/day of oral CBD tablets for three weeks per treatment period. The product contained more than 99% CBD and less than 0.1% THC.
6. Does this prove CBD never helps anxiety in cancer care?
No. It only studies one regimen, one population, and one short treatment window. That is far narrower than the broad question many readers may want answered.
7. Were there major safety concerns?
Adverse events were generally similar between CBD and placebo in this small sample. One participant developed a rash during CBD, possibly related to a carrier substance.
8. Why does early termination matter so much?
When a trial stops early and enrolls far fewer participants than planned, it becomes harder to detect true effects and easier to overread unstable results. The design may be good, but the precision is weak.
9. Should clinicians change practice based on this study alone?
It should lower confidence in this exact purified oral CBD strategy for this indication, but it should not be treated as the only evidence that matters. Clinical decisions still require broader context, patient priorities, and honest uncertainty.
10. What is the most careful takeaway?
This trial did not support benefit, and that matters. But because it was small and underpowered, the wisest interpretation is measured caution rather than sweeping certainty.
